Vanda Pharmaceuticals Competitors

Amgen (NASDAQ:AMGN) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Amgen and Vanda Pharmaceuticals, as provided by MarketBeat.com.

Amgen presently has a consensus target price of $254.08, indicating a potential upside of 15.33%. Vanda Pharmaceuticals has a consensus target price of $15.3333, indicating a potential upside of 26.62%. Given Vanda Pharmaceuticals' higher probable upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Amgen.

Earnings and Valuation

This table compares Amgen and Vanda Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Amgen has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500.

Insider and Institutional Ownership

71.7% of Amgen shares are owned by institutional investors. 0.4% of Amgen shares are owned by insiders. Comparatively, 5.9% of Vanda Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Amgen and Vanda Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Amgen beats Vanda Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Vanda Pharmaceuticals (NASDAQ:VNDA) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Risk and Volatility

Vanda Pharmaceuticals has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Institutional & Insider Ownership

77.9% of Gilead Sciences shares are owned by institutional investors. 5.9% of Vanda Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Vanda Pharmaceuticals and Gilead Sciences' gross revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Vanda Pharmaceuticals and Gilead Sciences, as provided by MarketBeat.com.

Vanda Pharmaceuticals currently has a consensus target price of $15.3333, suggesting a potential upside of 26.62%. Gilead Sciences has a consensus target price of $76.1538, suggesting a potential upside of 27.99%. Given Gilead Sciences' higher possible upside, analysts plainly believe Gilead Sciences is more favorable than Vanda Pharmaceuticals.

Profitability

This table compares Vanda Pharmaceuticals and Gilead Sciences' net margins, return on equity and return on assets.

Summary

Gilead Sciences beats Vanda Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Vanda Pharmaceuticals (NASDAQ:VNDA) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation.

Risk & Volatility

Vanda Pharmaceuticals has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Profitability

This table compares Vanda Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Institutional & Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 5.9% of Vanda Pharmaceuticals shares are held by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for Vanda Pharmaceuticals and Vertex Pharmaceuticals, as provided by MarketBeat.com.

Vanda Pharmaceuticals currently has a consensus target price of $15.3333, suggesting a potential upside of 26.62%. Vertex Pharmaceuticals has a consensus target price of $290.5862, suggesting a potential upside of 33.24%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Vanda Pharmaceuticals.

Valuation and Earnings

This table compares Vanda Pharmaceuticals and Vertex Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Vanda Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

Vanda Pharmaceuticals (NASDAQ:VNDA) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, profitability, risk and valuation.

Volatility & Risk

Vanda Pharmaceuticals has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Vanda Pharmaceuticals and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

Vanda Pharmaceuticals presently has a consensus target price of $15.3333, indicating a potential upside of 26.62%. Regeneron Pharmaceuticals has a consensus target price of $628.52, indicating a potential upside of 23.65%. Given Vanda Pharmaceuticals' higher possible upside, research analysts clearly believe Vanda Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Profitability

This table compares Vanda Pharmaceuticals and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

85.9% of Regeneron Pharmaceuticals shares are held by institutional investors. 5.9% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Vanda Pharmaceuticals and Regeneron Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Regeneron Pharmaceuticals beats Vanda Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Vanda Pharmaceuticals (NASDAQ:VNDA) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.

Earnings & Valuation

This table compares Vanda Pharmaceuticals and Biogen's top-line revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Vanda Pharmaceuticals has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.

Profitability

This table compares Vanda Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings and price targets for Vanda Pharmaceuticals and Biogen, as reported by MarketBeat.

Vanda Pharmaceuticals currently has a consensus price target of $15.3333, indicating a potential upside of 26.62%. Biogen has a consensus price target of $305.9032, indicating a potential upside of 26.54%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than Biogen.

Institutional and Insider Ownership

78.9% of Biogen shares are owned by institutional investors. 5.9% of Vanda Pharmaceuticals shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Biogen beats Vanda Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Vanda Pharmaceuticals (NASDAQ:VNDA) and Seagen (NASDAQ:SGEN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Analyst Ratings

This is a summary of current ratings and target prices for Vanda Pharmaceuticals and Seagen, as reported by MarketBeat.

Vanda Pharmaceuticals currently has a consensus price target of $15.3333, indicating a potential upside of 26.62%. Seagen has a consensus price target of $176.75, indicating a potential upside of 6.83%. Given Vanda Pharmaceuticals' higher probable upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Seagen.

Risk & Volatility

Vanda Pharmaceuticals has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Seagen has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.

Insider & Institutional Ownership

92.0% of Seagen shares are held by institutional investors. 5.9% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 31.1% of Seagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Vanda Pharmaceuticals and Seagen's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Vanda Pharmaceuticals and Seagen's revenue, earnings per share (EPS) and valuation.

Vanda Pharmaceuticals has higher earnings, but lower revenue than Seagen. Seagen is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Seagen beats Vanda Pharmaceuticals on 8 of the 15 factors compared between the two stocks.